Southeast Regional Radiation Medicine Center Obtains Domestic Clinical Approval for NK Cell Pancreatic Cancer Treatment by Korean Researchers

[Asia Economy Reporter Yoo Hyun-seok] The Dongnam Regional Radiation Medical Center, which is developing anticancer drugs in collaboration with MedicBioNK, an affiliate of Daechang Solution, has received approval from the Ministry of Food and Drug Safety for a clinical trial targeting pancreatic cancer patients.

According to the Ministry of Food and Drug Safety's Integrated Drug Information System on the 19th, the Dongnam Regional Radiation Medical Center received approval from the Ministry on the 17th for a clinical trial request titled "Safety evaluation of combined administration of standard treatment (Gemcitabine + Erlotinib) and Natural Killer Cell in patients with locally advanced and metastatic pancreatic cancer."

A representative of Daechang Solution stated, "It was confirmed that the investigator-initiated clinical trial was approved on the 17th," adding, "Daechang Solution has signed a technology agreement, and the medical center will conduct all clinical experiments." They further noted, "The exact clinical schedule should be confirmed through the Dongnam Regional Radiation Medical Center."

Daechang Solution's affiliate, MedicBioNK, signed a technology implementation contract last year with the Dongnam Regional Radiation Medical Center for anticancer treatment using Natural Killer Cells (NK cells). NK cells, also called "Natural Killer Cells," are a type of white blood cell responsible for innate immunity. They directly attack virus-infected cancer cells. Additionally, MedicBioNK was granted priority rights to implement anticancer drugs for cancers other than pancreatic cancer developed by the Dongnam Regional Radiation Medical Center.

MedicBioNK is a medical technology company specializing in NK cell-related technologies, established in February last year. It is a subsidiary in which MedicBio, a 100% subsidiary of Daechang Solution, holds the largest stake.

This content was produced with the assistance of AI translation services.